Information Journal Paper
APA:
Copy. (2018). A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Advances, 2(8), 825-831. SID. https://sid.ir/paper/745021/en
Vancouver:
Copy. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Advances[Internet]. 2018;2(8):825-831. Available from: https://sid.ir/paper/745021/en
IEEE:
Copy, “A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations,” Blood Advances, vol. 2, no. 8, pp. 825–831, 2018, [Online]. Available: https://sid.ir/paper/745021/en